An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Monoclonal antibodies (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphogen
- 29 Jun 2017 Dose of PAN-Her has increased from 2 to 4,number of arms has changed from 3 to 6,hence patient number also changed from 75 to 130.
- 22 Jun 2017 Planned number of patients changed from 75 to 131.
- 22 Jun 2017 Planned End Date changed from 1 Oct 2019 to 1 May 2020.